60 related articles for article (PubMed ID: 1625492)
1. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug.
Marie JP; Wdowik T; Bisserbe S; Zittoun R
Leukemia; 1992 Jul; 6(7):720-2. PubMed ID: 1625492
[TBL] [Abstract][Full Text] [Related]
2. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
[TBL] [Abstract][Full Text] [Related]
3. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
4. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.
Clavio M; Quintino S; Masoudi B; Carrara S; Cerri R; Pierri I; Canepa L; Miglino M; Muner P; Damasio E; Gobbi M
J Exp Clin Cancer Res; 2001 Jun; 20(2):165-73. PubMed ID: 11484970
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia.
Pashko S; Jacobs J; Santorsa J
Clin Ther; 1991; 13(3):353-60. PubMed ID: 1954636
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
7. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
Al Bahar S; Pandita R; Bavishi K; Savani B
Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
9. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Lemez P; Maresová J
Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
[TBL] [Abstract][Full Text] [Related]
12. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
13. Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS.
van Geel BM; Huijgens PC; Ossenkoppele GJ; Wijermans PW; Langenhuijsen MM
Neth J Med; 1989 Oct; 35(3-4):128-36. PubMed ID: 2601790
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience.
Head DR; Kopecky KJ; Willman C; Appelbaum FR
Leukemia; 1994; 8 Suppl 2():S38-41. PubMed ID: 7815835
[TBL] [Abstract][Full Text] [Related]
15. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
16. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.
Eardley AM; Heller G; Warrell RP
Leukemia; 1994 Jun; 8(6):934-9. PubMed ID: 8207987
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Daenen S; Löwenberg B; Sonneveld P; van Putten WL; Verhoef G; Verdonck LF; van Veldhoven M; Huijgens PC
Leukemia; 1994 Jan; 8(1):6-10. PubMed ID: 8289499
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence.
MacCallum PK; Davis CL; Rohatiner AZ; Lim J; Gupta RK; Whelan JS; Price CG; Evans ML; Amess JA; Leahy M
Leukemia; 1993 Oct; 7(10):1496-9. PubMed ID: 8412309
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Lemez P; Urbánek V
Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
